{"url_path":"/sec/nvcr/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1645113/0001645113-26-000056-index.html","accession_number":"0001645113-26-000056","cik":"0001645113","ticker":"NVCR","issuer_name":"NovoCure Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645113/0001645113-26-000056-index.html","primary_entity_key":"0001645113","primary_entity_name":"NovoCure Ltd"},"word_count":80,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits\n\n(d)    Exhibits\n\nExhibit No.Description\n\n99.1\n[Press Release of NovoCure Limited, dated June 30, 2026](paxtuvdecisionpr.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nNovoCure Limited\n\n(Registrant)\n\nDate: June 30, 2026\n\nBy: /s/ Christoph Brackmann\n\nName: Christoph Brackmann\n\nTitle: Chief Financial Officer"}